"We are pleased with the preliminary FULCRUM-VT acute data, which highlight the potential of Adagio's proprietary ULTC technology to transform treatment for patients with ventricular tachycardia,†said Todd Usen, Chief Executive Officer of Adagio Medical. "On behalf of the entire Adagio Medical team, I want to thank all of the investigators, research coordinators and patients who have supported this study and whose commitment to serving this underserved population of patients will bring us one step closer to ...